Martin, Valentina
Chiriaco, Cristina
Modica, Chiara
Acquadro, Anna
Cortese, Marco
Galimi, Francesco
Perera, Timothy
Gammaitoni, Loretta
Aglietta, Massimo
Comoglio, Paolo M.
Vigna, Elisa
Sangiolo, Dario
Article History
Received: 10 August 2018
Revised: 1 October 2018
Accepted: 3 October 2018
First Online: 6 February 2019
Competing interests
: P.M.C. and E.V. are co-founders of Metis Precision Medicine B-Corp (Italy). P.M.C. and T.P. are co-founders of OCTIMET Oncology NV (Belgium). OCTIMET Oncology is the current license holder for JNJ-605 (now OMO-0). The companies did not interfere in the design of the study, analysis of data and decision to publish. All the remaining authors declare no competing interest.
: The study was conducted in compliance with the provisions of the Declaration of Helsinki and in accordance with international standards of Good Clinical Practice. All patients provided informed consent provided informed consent for research use and the study was conducted according to a protocol approved by the institutional review board (ethics committee).
: <b>Funding:</b> This work was supported by the FPRC ONLUS 5 × 1000, Ministero della Salute 2012 to D.S. and E.V.; Ricerca Finalizzata-Giovani Ricercatori Ministero della Salute (GR-2011-02349197) to D.S.; AIRC MFAG 2014 N.15731 and AIRC IG 2017 N. 20259 to D.S.; AIRC IG 2014, N. 15572 to P.M.C.; AIRC Special Program 5 × 1000 2010 MCO, N. 9970 to P.M.C. and E.V.; FPRC ONLUS 5 × 1000 Ministero della Salute 2011, 2013, 2014 to P.M.C.; Italian Ministry of Health Ricerca Corrente 2017.